Carmofur

DB09010ApprovedWithdrawnSmall molecule

Carmofur is a derivative of fluorouracil, and is an antineoplastic agent that has been used in the treatment of breast and colorectal cancer. Carmofur has been known to induce leukoencephalopathy.

Mechanism: Pharmacologically active on Replicase polyprotein 1ab and Acid ceramidase
Curator reviewed
Formula / weight: C₁₁H₁₆FN₃O₃ · 257.2614 g/mol (avg)

Resolves to

Compound

UNIIHA82M3RAB2CAS61422-45-5ChEMBLCHEMBL460499ChEBI31360PubChem2577KEGGD01784

Clinical / RWD

ATCL01BC04

Structure

InChIKeyAOCCBINRVIKJHY-UHFFFAOYSA-NSMILESCCCCCCNC(=O)N1C=C(F)C(=O)NC1=O

Targets

P0DTD1repQ13510ASAH1

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

39Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 7 drug categories

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Carmofur, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In